Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionMacquarie Group Ltd
Latest Disclosed Ownership887,275 shares
Ownership 4.86%
Macquarie Group Ltd ownership in LGND / Ligand Pharmaceuticals Incorporated

2024-11-01 - Macquarie Group Ltd has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 887,275 shares of Ligand Pharmaceuticals Incorporated (US:LGND). This represents 4.86 percent ownership of the company. In their previous filing dated 2024-02-14 , Macquarie Group Ltd had reported owning 987,248 shares, indicating a decrease of -10.13 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2024-11-01 2024-11-01 13G/A 987,248 887,275 -10.13 4.86 -14.13
2024-02-14 2024-02-14 13G 624,969 987,248 57.97 5.66 51.34
2022-02-14 2022-02-14 13G/A 913,653 624,969 -31.60 3.74 -34.15
2021-02-12 2021-02-12 13G 913,653 5.68

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 0 -100.00 0
2025-11-13 2025-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 751,788 -174,766 -18.86 133,172 26.43 0.1554
2025-08-14 2025-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 926,554 20,327 2.24 105,331 10.55 0.1292
2025-08-14 2025-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 906,227 21,847 2.47 95,281 0.55 0.1183
2025-05-15 2025-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 906,227 21,847 95,281 0.0778
2025-02-14 2024-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 884,380 -2,895 -0.33 94,761 6.70 0.1150
2024-11-14 2024-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 887,275 -79,277 -8.20 88,807 9.04 0.0959
2024-08-09 2024-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 966,552 -66,629 -6.45 81,442 7.83 0.0934
2024-05-14 2024-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 1,033,181 45,827 4.64 75,526 7.10 0.0857
2024-02-14 2023-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 987,354 -4,464 -0.45 70,517 18.66 0.0815
2023-11-14 2023-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 991,818 154,648 18.47 59,430 -1.54 0.0747
2023-10-27 2023-06-30 13F/A-2 LIGAND PHARMACEUTICALS COM NEW 53220K504 837,170 19,187 2.35 60,360 0.32 0.0690
2023-10-12 2023-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 837,170 19,187 60,360 0.0607
2023-08-14 2023-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 837,170 19,187 60,360 0.0612
2023-06-01 2023-03-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 817,983 17,387 2.17 60,171 12.51 0.0715
2023-05-15 2023-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 817,983 17,387 60,171 0.0552
2023-02-21 2022-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 800,596 6,975 0.88 53,480 -21.75 0.0632
2022-11-14 2022-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 793,621 9,697 1.24 68,347 -2.28 0.0838
2022-08-17 2022-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 783,924 25,183 3.32 69,941 -18.05 0.0785
2022-08-15 2022-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 783,924 25,183 69,941 0.0251
2022-05-16 2022-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 758,741 133,772 21.40 85,351 -11.58 0.0649
2022-02-11 2021-12-31 13F Ligand Pharmaceuticals COM NEW 53220K504 624,969 -19,809 -3.07 96,532 7.46 0.0804
2021-11-12 2021-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 644,778 51,080 8.60 89,831 15.33 0.0766
2021-08-13 2021-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 593,698 109,340 22.57 77,888 5.48 0.0640
2021-05-14 2021-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 484,358 -410,320 -45.86 73,840 -17.01 0.1044
2021-02-16 2020-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 894,678 138,545 18.32 88,975 23.45 0.1299
2020-11-13 2020-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 756,133 14,080 1.90 72,074 -13.16 0.1220
2020-08-11 2020-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 742,053 48,968 7.07 82,999 64.67 0.1429
2020-05-15 2020-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 693,085 53,820 8.42 50,402 -24.40 0.1035
2020-03-18 2019-12-31 13F/A-2 LIGAND PHARMACEUTICALS COM NEW 53220K504 639,265 79,300 14.16 66,669 19.61 0.0952
2020-02-28 2019-12-31 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 639,265 0 66,669 0.0963
2020-02-14 2019-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 639,265 79,300 66,669 83,663.9449
2019-11-14 2019-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 559,965 34,128 6.49 55,739 -7.14 0.0934
2019-11-06 2019-06-30 13F/A-2 LIGAND PHARMACEUTICALS COM NEW 53220K504 525,837 35,055 7.14 60,024 -2.71 0.1012
2019-09-24 2019-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 525,837 0 60,024 0.1021
2019-08-14 2019-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 525,837 35,055 60,024
2019-05-15 2019-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 490,782 51,195 11.65 61,697 3.43 0.1052
2019-02-15 2018-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 439,587 65,712 17.58 59,652 -41.87 0.1153
2018-11-15 2018-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 373,875 -23,238 -5.85 102,625 24.74 0.1672
2019-03-21 2018-06-30 13F/A-1 LIGAND PHARMACEUTICALS COM NEW 53220K504 397,113 9,970 2.58 82,270 28.67 0.1419
2018-08-14 2018-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 397,113 9,970 82,270
2018-05-11 2018-03-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 387,143 18,420 5.00 63,941 26.64 0.1165
2018-02-14 2017-12-31 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 368,723 -94,312 -20.37 50,489 -19.91 0.0893
2017-11-08 2017-09-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 463,035 -8,023 -1.70 63,042 10.24 0.1131
2017-08-14 2017-06-30 13F LIGAND PHARMACEUTICALS COM NEW 53220K504 471,058 101,073 27.32 57,186 46.04 0.1045
2017-05-15 2017-03-31 13F Ligand Pharmaceuticals COM NEW 53220K504 369,985 40,820 12.40 39,159 17.08 0.0712
2017-03-30 2016-12-31 13F/A-1 Ligand Pharmaceuticals COMMON 53220K504 329,165 56,040 20.52 33,446 19.99 0.0640
2017-02-15 2016-12-31 13F Ligand Pharmaceuticals COMMON 53220K504 329,165 33,446
2016-11-15 2016-09-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 273,125 -8,504 -3.02 27,875 -17.01 0.0536
2016-09-14 2016-06-30 13F/A-1 LIGAND PHARMACEUTICALS COMMON 53220K504 281,629 10,716 3.96 33,590 15.78 0.0660
2016-08-15 2016-06-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 281,629 33,590
2016-05-16 2016-03-31 13F LIGAND PHARMACEUTICALS COMMON 53220K504 270,913 38,557 16.59 29,012 15.16 0.0585
2016-02-16 2015-12-31 13F LIGAND PHARMACEUTICALS COMMON 53220K504 232,356 -24,513 -9.54 25,192 14.50 0.0517
2015-11-16 2015-09-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 256,869 38,825 17.81 22,001 0.00 0.0472
2015-08-21 2015-06-30 13F/A-1 LIGAND PHARMACEUTICALS COMMON 53220K504 218,044 -12,080 -5.25 22,001 23.98 0.0436
2015-08-14 2015-06-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 218,044 22,001
2015-05-18 2015-03-31 13F LIGAND PHARMACEUTICALS COMMON 53220K504 230,124 93,264 68.15 17,745 143.68 0.0348
2015-02-17 2014-12-31 13F LIGAND PHARMACEUTICALS COMMON 53220K504 136,860 76,860 128.10 7,282 158.32 0.0150
2014-11-14 2014-09-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 60,000 0 0.00 2,819 -24.57 0.0060
2014-08-14 2014-06-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 60,000 0 0.00 3,737 -7.41 0.0083
2014-05-15 2014-03-31 13F LIGAND PHARMACEUTICALS Common 53220K504 60,000 0 0.00 4,036 27.88 0.0070
2014-02-14 2013-12-31 13F LIGAND PHARMACEUTICALS Common Stock 53220K504 60,000 -50,700 -45.80 3,156 -34.13 0.0057
2013-11-14 2013-09-30 13F LIGAND PHARMACEUTICALS Common Stock 53220K504 110,700 -14,300 -11.44 4,791 2.42 0.0094
2013-08-16 2013-06-30 13F/A-1 LIGAND PHARMACEUTICALS COMMON 53220K504 125,000 125,000 4,678 0.0102
2013-08-14 2013-06-30 13F LIGAND PHARMACEUTICALS COMMON 53220K504 125,000 4,678 0.0102
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.